Thiel Michael A, Steiger Jurg U, O'Connell Philip J, Lehnert Anne M, Coster Douglas J, Williams Keryn A
Department of Ophthalmology, Flinders University of South Australia, Adelaide, South Australia, Australia.
Clin Exp Ophthalmol. 2005 Apr;33(2):176-80. doi: 10.1111/j.1442-9071.2005.00974.x.
Costimulatory molecule blockade with antibody-based immunosuppressive agents has been shown to prolong the survival of many types of allograft. The effects were evaluated of local costimulatory molecule blockade with different CTLA4-Ig constructs and of systemic, short-term treatment with an anti-CD28 monoclonal antibody on orthotopic corneal allograft survival in the rat.
Adult Fischer-344 rats underwent Wistar-Furth orthotopic corneal grafts. The rats were treated with two different CTLA4-fusion proteins administered intraocularly in the perioperative period, or systemically with anti-CD28 monoclonal antibody JJ319. Corneal graft survival was determined by daily slit-lamp examination. The day of rejection was defined as the first postoperative day on which the iris margin was no longer clearly visible through the corneal graft.
Local administration of CTLA4-fusion protein with mutated immunoglobulin constant region domains via a single perioperative intraocular injection prolonged corneal graft survival modestly but significantly (P < 0.05), in contrast to a CTLA4-fusion protein with wild-type immunoglobulin domains, which had no effect on graft survival (P > 0.5). Systemic short-term administration of 400 microg total of an anti-CD28 monoclonal antibody also prolonged corneal graft survival significantly (P < 0.05) and was more effective than systemic administration of 2 mg total of CTLA4-fusion protein (P < 0.05).
Local administration of CTLA4-fusion protein with mutated (non-functional) immunoglobulin domains or systemic administration of anti-CD28 monoclonal antibody can prolong corneal allograft survival in the rat.
已证明使用基于抗体的免疫抑制剂阻断共刺激分子可延长多种类型同种异体移植物的存活时间。评估了用不同的CTLA4-Ig构建体进行局部共刺激分子阻断以及用抗CD28单克隆抗体进行全身短期治疗对大鼠原位角膜同种异体移植物存活的影响。
成年Fischer-344大鼠接受Wistar-Furth原位角膜移植。在围手术期,大鼠通过眼内注射两种不同的CTLA4融合蛋白进行治疗,或用抗CD28单克隆抗体JJ319进行全身治疗。通过每日裂隙灯检查确定角膜移植物的存活情况。排斥反应日定义为术后第一天,此时通过角膜移植物不再能清楚看到虹膜边缘。
与具有野生型免疫球蛋白结构域的CTLA4融合蛋白对移植物存活无影响(P>0.5)相反,通过围手术期单次眼内注射给予具有突变免疫球蛋白恒定区结构域的CTLA4融合蛋白可适度但显著地延长角膜移植物存活时间(P<0.05)。总共400μg抗CD28单克隆抗体的全身短期给药也显著延长了角膜移植物存活时间(P<0.05),并且比总共2mg CTLA4融合蛋白的全身给药更有效(P<0.05)。
局部给予具有突变(无功能)免疫球蛋白结构域的CTLA4融合蛋白或全身给予抗CD28单克隆抗体可延长大鼠角膜同种异体移植物的存活时间。